Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Identifieur interne : 000238 ( Main/Exploration ); précédent : 000237; suivant : 000239Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Auteurs : Kei Kawaguchi [Japon] ; Takashi Higuchi [États-Unis] ; Shukuan Li [États-Unis] ; Qinghong Han [États-Unis] ; Yuying Tan [États-Unis] ; Kentaro Igarashi [États-Unis] ; Ming Zhao [États-Unis] ; Kentaro Miyake [États-Unis] ; Tasuku Kiyuna [États-Unis] ; Masuyo Miyake [États-Unis] ; Hiromichi Ohshiro [États-Unis] ; Norihiko Sugisawa [Japon] ; Zhiying Zhang [États-Unis] ; Sahar Razmjooei [États-Unis] ; Sintawat Wangsiricharoen [États-Unis] ; Bartosz Chmielowski [États-Unis] ; Scott D. Nelson [États-Unis] ; Tara A. Russell [États-Unis] ; Sarah M. Dry [États-Unis] ; Yunfeng Li [États-Unis] ; Mark A. Eckardt [États-Unis] ; Arun S. Singh [États-Unis] ; Shree Ram Singh [États-Unis] ; Fritz C. Eilber [États-Unis] ; Michiaki Unno [Japon] ; Robert M. Hoffman [États-Unis]Source :
- Biochemical and biophysical research communications [ 1090-2104 ] ; 2018.
Descripteurs français
- KwdFr :
- Administration par voie orale (MeSH), Animaux (MeSH), Antimétabolites antinéoplasiques (usage thérapeutique), Antinéoplasiques (administration et posologie), Antinéoplasiques (usage thérapeutique), Carbon-sulfur lyases (administration et posologie), Carbon-sulfur lyases (usage thérapeutique), Humains (MeSH), Modèles animaux de maladie humaine (MeSH), Mutation ponctuelle (MeSH), Mâle (MeSH), Mélanome (anatomopathologie), Mélanome (génétique), Mélanome (microbiologie), Mélanome (thérapie), Protéines proto-oncogènes B-raf (génétique), Protéines recombinantes (administration et posologie), Protéines recombinantes (usage thérapeutique), Pseudomonas putida (enzymologie), Salmonella typhimurium (physiologie), Souris nude (MeSH), Systèmes de délivrance de médicaments (MeSH), Témozolomide (administration et posologie), Témozolomide (usage thérapeutique).
- MESH :
- administration et posologie : Antinéoplasiques, Carbon-sulfur lyases, Protéines recombinantes, Témozolomide.
- anatomopathologie : Mélanome.
- enzymologie : Pseudomonas putida.
- génétique : Mélanome, Protéines proto-oncogènes B-raf.
- microbiologie : Mélanome.
- physiologie : Salmonella typhimurium.
- thérapie : Mélanome.
- usage thérapeutique : Antimétabolites antinéoplasiques, Antinéoplasiques, Carbon-sulfur lyases, Protéines recombinantes, Témozolomide.
- Administration par voie orale, Animaux, Humains, Modèles animaux de maladie humaine, Mutation ponctuelle, Mâle, Souris nude, Systèmes de délivrance de médicaments.
English descriptors
- KwdEn :
- Administration, Oral (MeSH), Animals (MeSH), Antimetabolites, Antineoplastic (therapeutic use), Antineoplastic Agents (administration & dosage), Antineoplastic Agents (therapeutic use), Carbon-Sulfur Lyases (administration & dosage), Carbon-Sulfur Lyases (therapeutic use), Disease Models, Animal (MeSH), Drug Delivery Systems (MeSH), Humans (MeSH), Male (MeSH), Melanoma (genetics), Melanoma (microbiology), Melanoma (pathology), Melanoma (therapy), Mice, Nude (MeSH), Point Mutation (MeSH), Proto-Oncogene Proteins B-raf (genetics), Pseudomonas putida (enzymology), Recombinant Proteins (administration & dosage), Recombinant Proteins (therapeutic use), Salmonella typhimurium (physiology), Temozolomide (administration & dosage), Temozolomide (therapeutic use).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Carbon-Sulfur Lyases, Recombinant Proteins, Temozolomide.
- chemical , genetics : Proto-Oncogene Proteins B-raf.
- chemical , therapeutic use : Antimetabolites, Antineoplastic, Antineoplastic Agents, Carbon-Sulfur Lyases, Recombinant Proteins, Temozolomide.
- enzymology : Pseudomonas putida.
- genetics : Melanoma.
- microbiology : Melanoma.
- pathology : Melanoma.
- physiology : Salmonella typhimurium.
- therapy : Melanoma.
- Administration, Oral, Animals, Disease Models, Animal, Drug Delivery Systems, Humans, Male, Mice, Nude, Point Mutation.
Abstract
Melanoma is a recalcitrant cancer. To improve and individualize treatment for this disease, we previously developed a patient-derived orthotopic xenograft (PDOX) model for melanoma. We previously reported the individual efficacy of tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) and recombinant methioninase (rMETase) for melanoma in the PDOX models of this disease. In the present study, we evaluated the efficacy of the combination of S. typhimurium A1-R with orally-administered rMETase (o-rMETase) for BRAF-V600E-negative melanoma in a PDOX model. Three weeks after implantation, 60 PDOX mouse models were randomized into six groups of 10 mice each: untreated control, temozolomide (TEM); o-rMETase; S. typhimurium A1-R; TEM + rMETase, S. typhimurium A1-R + rMETase. All treatments inhibited tumor growth compared to untreated control (TEM: p < 0.0001, rMETase: p < 0.0001, S. typhimurium A1-R: p < 0.0001, TEM + rMETase: p < 0.0001, S. typhimurium A1-R + rMETase: p < 0.0001). The most effective was the combination of S. typhimurium A1-R + o-rMETase which regressed this melanoma PDOX, thereby indicating a new paradigm for treatment of metastatic melanoma.
DOI: 10.1016/j.bbrc.2018.08.097
PubMed: 30166061
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.</title><author><name sortKey="Kawaguchi, Kei" sort="Kawaguchi, Kei" uniqKey="Kawaguchi K" first="Kei" last="Kawaguchi">Kei Kawaguchi</name><affiliation wicri:level="1"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai</wicri:regionArea><wicri:noRegion>Sendai</wicri:noRegion></affiliation></author><author><name sortKey="Higuchi, Takashi" sort="Higuchi, Takashi" uniqKey="Higuchi T" first="Takashi" last="Higuchi">Takashi Higuchi</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Li, Shukuan" sort="Li, Shukuan" uniqKey="Li S" first="Shukuan" last="Li">Shukuan Li</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Han, Qinghong" sort="Han, Qinghong" uniqKey="Han Q" first="Qinghong" last="Han">Qinghong Han</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Tan, Yuying" sort="Tan, Yuying" uniqKey="Tan Y" first="Yuying" last="Tan">Yuying Tan</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Igarashi, Kentaro" sort="Igarashi, Kentaro" uniqKey="Igarashi K" first="Kentaro" last="Igarashi">Kentaro Igarashi</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Zhao, Ming" sort="Zhao, Ming" uniqKey="Zhao M" first="Ming" last="Zhao">Ming Zhao</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Miyake, Kentaro" sort="Miyake, Kentaro" uniqKey="Miyake K" first="Kentaro" last="Miyake">Kentaro Miyake</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kiyuna, Tasuku" sort="Kiyuna, Tasuku" uniqKey="Kiyuna T" first="Tasuku" last="Kiyuna">Tasuku Kiyuna</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Miyake, Masuyo" sort="Miyake, Masuyo" uniqKey="Miyake M" first="Masuyo" last="Miyake">Masuyo Miyake</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ohshiro, Hiromichi" sort="Ohshiro, Hiromichi" uniqKey="Ohshiro H" first="Hiromichi" last="Ohshiro">Hiromichi Ohshiro</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Sugisawa, Norihiko" sort="Sugisawa, Norihiko" uniqKey="Sugisawa N" first="Norihiko" last="Sugisawa">Norihiko Sugisawa</name><affiliation wicri:level="1"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai</wicri:regionArea><wicri:noRegion>Sendai</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Zhiying" sort="Zhang, Zhiying" uniqKey="Zhang Z" first="Zhiying" last="Zhang">Zhiying Zhang</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Razmjooei, Sahar" sort="Razmjooei, Sahar" uniqKey="Razmjooei S" first="Sahar" last="Razmjooei">Sahar Razmjooei</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wangsiricharoen, Sintawat" sort="Wangsiricharoen, Sintawat" uniqKey="Wangsiricharoen S" first="Sintawat" last="Wangsiricharoen">Sintawat Wangsiricharoen</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Chmielowski, Bartosz" sort="Chmielowski, Bartosz" uniqKey="Chmielowski B" first="Bartosz" last="Chmielowski">Bartosz Chmielowski</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology-Oncology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Nelson, Scott D" sort="Nelson, Scott D" uniqKey="Nelson S" first="Scott D" last="Nelson">Scott D. Nelson</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Russell, Tara A" sort="Russell, Tara A" uniqKey="Russell T" first="Tara A" last="Russell">Tara A. Russell</name><affiliation wicri:level="2"><nlm:affiliation>Division of Surgical Oncology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Surgical Oncology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dry, Sarah M" sort="Dry, Sarah M" uniqKey="Dry S" first="Sarah M" last="Dry">Sarah M. Dry</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Li, Yunfeng" sort="Li, Yunfeng" uniqKey="Li Y" first="Yunfeng" last="Li">Yunfeng Li</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Eckardt, Mark A" sort="Eckardt, Mark A" uniqKey="Eckardt M" first="Mark A" last="Eckardt">Mark A. Eckardt</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Yale School of Medicine, New Haven, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Surgery, Yale School of Medicine, New Haven, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Singh, Arun S" sort="Singh, Arun S" uniqKey="Singh A" first="Arun S" last="Singh">Arun S. Singh</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology-Oncology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Singh, Shree Ram" sort="Singh, Shree Ram" uniqKey="Singh S" first="Shree Ram" last="Singh">Shree Ram Singh</name><affiliation wicri:level="2"><nlm:affiliation>Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Basic Research Laboratory, National Cancer Institute, Frederick, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Eilber, Fritz C" sort="Eilber, Fritz C" uniqKey="Eilber F" first="Fritz C" last="Eilber">Fritz C. Eilber</name><affiliation wicri:level="2"><nlm:affiliation>Division of Surgical Oncology, University of California, Los Angeles, CA, USA. Electronic address: fceilber@mednet.ucla.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Surgical Oncology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Unno, Michiaki" sort="Unno, Michiaki" uniqKey="Unno M" first="Michiaki" last="Unno">Michiaki Unno</name><affiliation wicri:level="4"><nlm:affiliation>Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan. Electronic address: m_unno@surg1.med.tohoku.ac.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai</wicri:regionArea><orgName type="university">Université du Tōhoku</orgName><placeName><settlement type="city">Sendai</settlement><region type="province">Région de Tōhoku</region></placeName></affiliation></author><author><name sortKey="Hoffman, Robert M" sort="Hoffman, Robert M" uniqKey="Hoffman R" first="Robert M" last="Hoffman">Robert M. Hoffman</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:30166061</idno><idno type="pmid">30166061</idno><idno type="doi">10.1016/j.bbrc.2018.08.097</idno><idno type="wicri:Area/Main/Corpus">000211</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000211</idno><idno type="wicri:Area/Main/Curation">000211</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000211</idno><idno type="wicri:Area/Main/Exploration">000211</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.</title><author><name sortKey="Kawaguchi, Kei" sort="Kawaguchi, Kei" uniqKey="Kawaguchi K" first="Kei" last="Kawaguchi">Kei Kawaguchi</name><affiliation wicri:level="1"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai</wicri:regionArea><wicri:noRegion>Sendai</wicri:noRegion></affiliation></author><author><name sortKey="Higuchi, Takashi" sort="Higuchi, Takashi" uniqKey="Higuchi T" first="Takashi" last="Higuchi">Takashi Higuchi</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Li, Shukuan" sort="Li, Shukuan" uniqKey="Li S" first="Shukuan" last="Li">Shukuan Li</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Han, Qinghong" sort="Han, Qinghong" uniqKey="Han Q" first="Qinghong" last="Han">Qinghong Han</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Tan, Yuying" sort="Tan, Yuying" uniqKey="Tan Y" first="Yuying" last="Tan">Yuying Tan</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Igarashi, Kentaro" sort="Igarashi, Kentaro" uniqKey="Igarashi K" first="Kentaro" last="Igarashi">Kentaro Igarashi</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Zhao, Ming" sort="Zhao, Ming" uniqKey="Zhao M" first="Ming" last="Zhao">Ming Zhao</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Miyake, Kentaro" sort="Miyake, Kentaro" uniqKey="Miyake K" first="Kentaro" last="Miyake">Kentaro Miyake</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kiyuna, Tasuku" sort="Kiyuna, Tasuku" uniqKey="Kiyuna T" first="Tasuku" last="Kiyuna">Tasuku Kiyuna</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Miyake, Masuyo" sort="Miyake, Masuyo" uniqKey="Miyake M" first="Masuyo" last="Miyake">Masuyo Miyake</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ohshiro, Hiromichi" sort="Ohshiro, Hiromichi" uniqKey="Ohshiro H" first="Hiromichi" last="Ohshiro">Hiromichi Ohshiro</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Sugisawa, Norihiko" sort="Sugisawa, Norihiko" uniqKey="Sugisawa N" first="Norihiko" last="Sugisawa">Norihiko Sugisawa</name><affiliation wicri:level="1"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai</wicri:regionArea><wicri:noRegion>Sendai</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Zhiying" sort="Zhang, Zhiying" uniqKey="Zhang Z" first="Zhiying" last="Zhang">Zhiying Zhang</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Razmjooei, Sahar" sort="Razmjooei, Sahar" uniqKey="Razmjooei S" first="Sahar" last="Razmjooei">Sahar Razmjooei</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wangsiricharoen, Sintawat" sort="Wangsiricharoen, Sintawat" uniqKey="Wangsiricharoen S" first="Sintawat" last="Wangsiricharoen">Sintawat Wangsiricharoen</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Chmielowski, Bartosz" sort="Chmielowski, Bartosz" uniqKey="Chmielowski B" first="Bartosz" last="Chmielowski">Bartosz Chmielowski</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology-Oncology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Nelson, Scott D" sort="Nelson, Scott D" uniqKey="Nelson S" first="Scott D" last="Nelson">Scott D. Nelson</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Russell, Tara A" sort="Russell, Tara A" uniqKey="Russell T" first="Tara A" last="Russell">Tara A. Russell</name><affiliation wicri:level="2"><nlm:affiliation>Division of Surgical Oncology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Surgical Oncology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dry, Sarah M" sort="Dry, Sarah M" uniqKey="Dry S" first="Sarah M" last="Dry">Sarah M. Dry</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Li, Yunfeng" sort="Li, Yunfeng" uniqKey="Li Y" first="Yunfeng" last="Li">Yunfeng Li</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Eckardt, Mark A" sort="Eckardt, Mark A" uniqKey="Eckardt M" first="Mark A" last="Eckardt">Mark A. Eckardt</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Yale School of Medicine, New Haven, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Surgery, Yale School of Medicine, New Haven, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Singh, Arun S" sort="Singh, Arun S" uniqKey="Singh A" first="Arun S" last="Singh">Arun S. Singh</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology-Oncology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Singh, Shree Ram" sort="Singh, Shree Ram" uniqKey="Singh S" first="Shree Ram" last="Singh">Shree Ram Singh</name><affiliation wicri:level="2"><nlm:affiliation>Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Basic Research Laboratory, National Cancer Institute, Frederick, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Eilber, Fritz C" sort="Eilber, Fritz C" uniqKey="Eilber F" first="Fritz C" last="Eilber">Fritz C. Eilber</name><affiliation wicri:level="2"><nlm:affiliation>Division of Surgical Oncology, University of California, Los Angeles, CA, USA. Electronic address: fceilber@mednet.ucla.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Surgical Oncology, University of California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Unno, Michiaki" sort="Unno, Michiaki" uniqKey="Unno M" first="Michiaki" last="Unno">Michiaki Unno</name><affiliation wicri:level="4"><nlm:affiliation>Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan. Electronic address: m_unno@surg1.med.tohoku.ac.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai</wicri:regionArea><orgName type="university">Université du Tōhoku</orgName><placeName><settlement type="city">Sendai</settlement><region type="province">Région de Tōhoku</region></placeName></affiliation></author><author><name sortKey="Hoffman, Robert M" sort="Hoffman, Robert M" uniqKey="Hoffman R" first="Robert M" last="Hoffman">Robert M. Hoffman</name><affiliation wicri:level="2"><nlm:affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Biochemical and biophysical research communications</title><idno type="eISSN">1090-2104</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral (MeSH)</term><term>Animals (MeSH)</term><term>Antimetabolites, Antineoplastic (therapeutic use)</term><term>Antineoplastic Agents (administration & dosage)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Carbon-Sulfur Lyases (administration & dosage)</term><term>Carbon-Sulfur Lyases (therapeutic use)</term><term>Disease Models, Animal (MeSH)</term><term>Drug Delivery Systems (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Melanoma (genetics)</term><term>Melanoma (microbiology)</term><term>Melanoma (pathology)</term><term>Melanoma (therapy)</term><term>Mice, Nude (MeSH)</term><term>Point Mutation (MeSH)</term><term>Proto-Oncogene Proteins B-raf (genetics)</term><term>Pseudomonas putida (enzymology)</term><term>Recombinant Proteins (administration & dosage)</term><term>Recombinant Proteins (therapeutic use)</term><term>Salmonella typhimurium (physiology)</term><term>Temozolomide (administration & dosage)</term><term>Temozolomide (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale (MeSH)</term><term>Animaux (MeSH)</term><term>Antimétabolites antinéoplasiques (usage thérapeutique)</term><term>Antinéoplasiques (administration et posologie)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Carbon-sulfur lyases (administration et posologie)</term><term>Carbon-sulfur lyases (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Modèles animaux de maladie humaine (MeSH)</term><term>Mutation ponctuelle (MeSH)</term><term>Mâle (MeSH)</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (génétique)</term><term>Mélanome (microbiologie)</term><term>Mélanome (thérapie)</term><term>Protéines proto-oncogènes B-raf (génétique)</term><term>Protéines recombinantes (administration et posologie)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Pseudomonas putida (enzymologie)</term><term>Salmonella typhimurium (physiologie)</term><term>Souris nude (MeSH)</term><term>Systèmes de délivrance de médicaments (MeSH)</term><term>Témozolomide (administration et posologie)</term><term>Témozolomide (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term><term>Carbon-Sulfur Lyases</term><term>Recombinant Proteins</term><term>Temozolomide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Proto-Oncogene Proteins B-raf</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Antineoplastic Agents</term><term>Carbon-Sulfur Lyases</term><term>Recombinant Proteins</term><term>Temozolomide</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term><term>Carbon-sulfur lyases</term><term>Protéines recombinantes</term><term>Témozolomide</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Pseudomonas putida</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Pseudomonas putida</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Mélanome</term><term>Protéines proto-oncogènes B-raf</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Salmonella typhimurium</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Salmonella typhimurium</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antimétabolites antinéoplasiques</term><term>Antinéoplasiques</term><term>Carbon-sulfur lyases</term><term>Protéines recombinantes</term><term>Témozolomide</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Disease Models, Animal</term><term>Drug Delivery Systems</term><term>Humans</term><term>Male</term><term>Mice, Nude</term><term>Point Mutation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Animaux</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Mutation ponctuelle</term><term>Mâle</term><term>Souris nude</term><term>Systèmes de délivrance de médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Melanoma is a recalcitrant cancer. To improve and individualize treatment for this disease, we previously developed a patient-derived orthotopic xenograft (PDOX) model for melanoma. We previously reported the individual efficacy of tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) and recombinant methioninase (rMETase) for melanoma in the PDOX models of this disease. In the present study, we evaluated the efficacy of the combination of S. typhimurium A1-R with orally-administered rMETase (o-rMETase) for BRAF-V600E-negative melanoma in a PDOX model. Three weeks after implantation, 60 PDOX mouse models were randomized into six groups of 10 mice each: untreated control, temozolomide (TEM); o-rMETase; S. typhimurium A1-R; TEM + rMETase, S. typhimurium A1-R + rMETase. All treatments inhibited tumor growth compared to untreated control (TEM: p < 0.0001, rMETase: p < 0.0001, S. typhimurium A1-R: p < 0.0001, TEM + rMETase: p < 0.0001, S. typhimurium A1-R + rMETase: p < 0.0001). The most effective was the combination of S. typhimurium A1-R + o-rMETase which regressed this melanoma PDOX, thereby indicating a new paradigm for treatment of metastatic melanoma.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30166061</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN><JournalIssue CitedMedium="Internet"><Volume>503</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>09</Month><Day>18</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation></Journal><ArticleTitle>Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.</ArticleTitle><Pagination><MedlinePgn>3086-3092</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0006-291X(18)31781-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2018.08.097</ELocationID><Abstract><AbstractText>Melanoma is a recalcitrant cancer. To improve and individualize treatment for this disease, we previously developed a patient-derived orthotopic xenograft (PDOX) model for melanoma. We previously reported the individual efficacy of tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) and recombinant methioninase (rMETase) for melanoma in the PDOX models of this disease. In the present study, we evaluated the efficacy of the combination of S. typhimurium A1-R with orally-administered rMETase (o-rMETase) for BRAF-V600E-negative melanoma in a PDOX model. Three weeks after implantation, 60 PDOX mouse models were randomized into six groups of 10 mice each: untreated control, temozolomide (TEM); o-rMETase; S. typhimurium A1-R; TEM + rMETase, S. typhimurium A1-R + rMETase. All treatments inhibited tumor growth compared to untreated control (TEM: p < 0.0001, rMETase: p < 0.0001, S. typhimurium A1-R: p < 0.0001, TEM + rMETase: p < 0.0001, S. typhimurium A1-R + rMETase: p < 0.0001). The most effective was the combination of S. typhimurium A1-R + o-rMETase which regressed this melanoma PDOX, thereby indicating a new paradigm for treatment of metastatic melanoma.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shukuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Qinghong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yuying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igarashi</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyake</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyuna</LastName><ForeName>Tasuku</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyake</LastName><ForeName>Masuyo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohshiro</LastName><ForeName>Hiromichi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugisawa</LastName><ForeName>Norihiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhiying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razmjooei</LastName><ForeName>Sahar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wangsiricharoen</LastName><ForeName>Sintawat</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chmielowski</LastName><ForeName>Bartosz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Tara A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dry</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yunfeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckardt</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Arun S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Shree Ram</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eilber</LastName><ForeName>Fritz C</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, University of California, Los Angeles, CA, USA. Electronic address: fceilber@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unno</LastName><ForeName>Michiaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan. Electronic address: m_unno@surg1.med.tohoku.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.4.-</RegistryNumber><NameOfSubstance UI="D013437">Carbon-Sulfur Lyases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.4.1.11</RegistryNumber><NameOfSubstance UI="C021558">L-methionine gamma-lyase</NameOfSubstance></Chemical><Chemical><RegistryNumber>YF1K15M17Y</RegistryNumber><NameOfSubstance UI="D000077204">Temozolomide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013437" MajorTopicYN="N">Carbon-Sulfur Lyases</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016958" MajorTopicYN="N">Pseudomonas putida</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012486" MajorTopicYN="Y">Salmonella typhimurium</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077204" MajorTopicYN="N">Temozolomide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">BRAF-V600E-negative melanoma</Keyword><Keyword MajorTopicYN="Y">Methionine dependence</Keyword><Keyword MajorTopicYN="Y">Nude mice</Keyword><Keyword MajorTopicYN="Y">PDOX</Keyword><Keyword MajorTopicYN="Y">Precision therapy</Keyword><Keyword MajorTopicYN="Y">Recombinant methioninase</Keyword><Keyword MajorTopicYN="Y">Salmonella typhimurium A1-R</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30166061</ArticleId><ArticleId IdType="pii">S0006-291X(18)31781-9</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2018.08.097</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li><li>États-Unis</li></country><region><li>Californie</li><li>Connecticut</li><li>Maryland</li><li>Région de Tōhoku</li></region><settlement><li>Sendai</li></settlement><orgName><li>Université du Tōhoku</li></orgName></list><tree><country name="Japon"><noRegion><name sortKey="Kawaguchi, Kei" sort="Kawaguchi, Kei" uniqKey="Kawaguchi K" first="Kei" last="Kawaguchi">Kei Kawaguchi</name></noRegion><name sortKey="Sugisawa, Norihiko" sort="Sugisawa, Norihiko" uniqKey="Sugisawa N" first="Norihiko" last="Sugisawa">Norihiko Sugisawa</name><name sortKey="Unno, Michiaki" sort="Unno, Michiaki" uniqKey="Unno M" first="Michiaki" last="Unno">Michiaki Unno</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Higuchi, Takashi" sort="Higuchi, Takashi" uniqKey="Higuchi T" first="Takashi" last="Higuchi">Takashi Higuchi</name></region><name sortKey="Chmielowski, Bartosz" sort="Chmielowski, Bartosz" uniqKey="Chmielowski B" first="Bartosz" last="Chmielowski">Bartosz Chmielowski</name><name sortKey="Dry, Sarah M" sort="Dry, Sarah M" uniqKey="Dry S" first="Sarah M" last="Dry">Sarah M. Dry</name><name sortKey="Eckardt, Mark A" sort="Eckardt, Mark A" uniqKey="Eckardt M" first="Mark A" last="Eckardt">Mark A. Eckardt</name><name sortKey="Eilber, Fritz C" sort="Eilber, Fritz C" uniqKey="Eilber F" first="Fritz C" last="Eilber">Fritz C. Eilber</name><name sortKey="Han, Qinghong" sort="Han, Qinghong" uniqKey="Han Q" first="Qinghong" last="Han">Qinghong Han</name><name sortKey="Hoffman, Robert M" sort="Hoffman, Robert M" uniqKey="Hoffman R" first="Robert M" last="Hoffman">Robert M. Hoffman</name><name sortKey="Igarashi, Kentaro" sort="Igarashi, Kentaro" uniqKey="Igarashi K" first="Kentaro" last="Igarashi">Kentaro Igarashi</name><name sortKey="Kiyuna, Tasuku" sort="Kiyuna, Tasuku" uniqKey="Kiyuna T" first="Tasuku" last="Kiyuna">Tasuku Kiyuna</name><name sortKey="Li, Shukuan" sort="Li, Shukuan" uniqKey="Li S" first="Shukuan" last="Li">Shukuan Li</name><name sortKey="Li, Yunfeng" sort="Li, Yunfeng" uniqKey="Li Y" first="Yunfeng" last="Li">Yunfeng Li</name><name sortKey="Miyake, Kentaro" sort="Miyake, Kentaro" uniqKey="Miyake K" first="Kentaro" last="Miyake">Kentaro Miyake</name><name sortKey="Miyake, Masuyo" sort="Miyake, Masuyo" uniqKey="Miyake M" first="Masuyo" last="Miyake">Masuyo Miyake</name><name sortKey="Nelson, Scott D" sort="Nelson, Scott D" uniqKey="Nelson S" first="Scott D" last="Nelson">Scott D. Nelson</name><name sortKey="Ohshiro, Hiromichi" sort="Ohshiro, Hiromichi" uniqKey="Ohshiro H" first="Hiromichi" last="Ohshiro">Hiromichi Ohshiro</name><name sortKey="Razmjooei, Sahar" sort="Razmjooei, Sahar" uniqKey="Razmjooei S" first="Sahar" last="Razmjooei">Sahar Razmjooei</name><name sortKey="Russell, Tara A" sort="Russell, Tara A" uniqKey="Russell T" first="Tara A" last="Russell">Tara A. Russell</name><name sortKey="Singh, Arun S" sort="Singh, Arun S" uniqKey="Singh A" first="Arun S" last="Singh">Arun S. Singh</name><name sortKey="Singh, Shree Ram" sort="Singh, Shree Ram" uniqKey="Singh S" first="Shree Ram" last="Singh">Shree Ram Singh</name><name sortKey="Tan, Yuying" sort="Tan, Yuying" uniqKey="Tan Y" first="Yuying" last="Tan">Yuying Tan</name><name sortKey="Wangsiricharoen, Sintawat" sort="Wangsiricharoen, Sintawat" uniqKey="Wangsiricharoen S" first="Sintawat" last="Wangsiricharoen">Sintawat Wangsiricharoen</name><name sortKey="Zhang, Zhiying" sort="Zhang, Zhiying" uniqKey="Zhang Z" first="Zhiying" last="Zhang">Zhiying Zhang</name><name sortKey="Zhao, Ming" sort="Zhao, Ming" uniqKey="Zhao M" first="Ming" last="Zhao">Ming Zhao</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/SulfurTransferaseV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000238 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000238 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= SulfurTransferaseV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30166061
|texte= Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30166061" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SulfurTransferaseV1
| This area was generated with Dilib version V0.6.38. |  |